Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$1.26 USD
-0.05 (-3.82%)
Updated May 10, 2024 03:59 PM ET
After-Market: $1.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HEPA 1.26 -0.05(-3.82%)
Will HEPA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HEPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HEPA
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
HEPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?
Other News for HEPA
Biotech Alert: Searches spiking for these stocks today
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session
Gold Falls Sharply; Matterport Shares Spike Higher
Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts